ANICCA-Class II : A phase II Trial of nivolumab in strong class II expressing microsatellite stable colorectal cancer patients (MSS CRC)

Short title	ANICCA-Class II : A phase II Trial of nivolumab in strong class II expressing microsatellite stable colorectal cancer patients (MSS CRC)
Status	Active
Effective start/end date	1/01/18 → 31/12/23

Project Details